
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is expected to experience steady earnings growth, with projections of GAAP earnings reaching $4.73 per diluted share in 2025 and $5.17 in 2026, reflecting ongoing strength in the Human Nutrition and Health segment. The company's second quarter of 2025 demonstrated a slight revenue increase to $255.5 million, surpassing expectations and showing consistency compared to previous quarters and the prior year. Additionally, improvements in gross and net margins are anticipated, alongside a potential pathway to becoming debt-free by the end of 2025, which positions the company favorably for future growth and possible mergers and acquisitions.
Bears say
The financial outlook for Balchem Corp appears bleak due to a decline in the applicable P/E multiple, which has dropped from 39.6x to 37.9x, indicating weakening investor confidence and a sluggish performance in revenue and earnings relative to its comparables. Additionally, the company's most recent quarterly results revealed sales in the Animal Nutrition and Health segment missed estimates by approximately $3.6 million, while the Industrial Products segment also fell short by $200,000, suggesting ongoing struggles in achieving growth targets. Furthermore, several identified risks, including slower-than-anticipated business growth, inflationary pressures, and potential disruptions from regional conflicts, compound the negative sentiment surrounding Balchem's financial stability and future performance.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares